Pemetrexed is a multi-targeted anti-folate agent with low toxicity and broad-spectrum anti-tumor activity. Pemetrexed combined with platinum is a therapy recommended by NCCN guidelines and CSCO guidelines for the first-line and maintenance treatment of advanced non-squamous NSCLC and advanced malignant pleural mesothelioma (MPM), which can significantly improve the efficacy of traditional chemotherapy and prolong the survival of patients.